Time-influencing factors for biochemical progression following radical prostatectomy;Factores influyentes en el tiempo hasta la progresión bioquímica después de prostatectomía radical

Actas Urologicas Espanolas

Volumn 35, Issue 4, 2011, Pages 201-207

  Barba, J ^a   Brugarolas, X ^a   Tolosa, E ^a   Rincon A ^a   Romero, L ^a   Rosell, D ^a   Robles, J E ^a   Zudaire, J J ^a   Berian, J M ^a   Pascual, J I ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Biochemical progression; Prognostic factors; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; ARTICLE; BIOPSY; BLOOD; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LYMPHADENECTOMY; MALE; METASTASIS; METHODOLOGY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

ADENOCARCINOMA; BIOPSY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 79953300050     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2010.08.008     Document Type: Article

References (33)

1. Ojea Calvo A, Mosteiro Cerviño MJ, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J. The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progression of the prostate cancer after radical prostatectomy. Actas Urol Esp. 2004;28:650-60.
2. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int. 2001;87:423-30. (Pubitemid 32242787)
3. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22:537-56. (Pubitemid 41079783)
4. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, Van Poppel H, et al. Guidelines on Prostate Cancer. Guidelines, European Association of Urology. Arnhem: EAU Guidelines Office; 2006.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-7. (Pubitemid 29211767)
6. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152(5 Pt 2):1837-42. (Pubitemid 24322641)
7. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43:12-27. (Pubitemid 36134310)
8. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol. 1989;141:873.
9. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol. 2001;165:1146.
10. Rioja Zuazu J, Zudaire Berbera JJ, Rincón Mayans A, Rosell Costa D, Robles García JE, Berian Polo JM. Gleason score 8-10 prostatic adenocarcinoma: prognostic influence in the biochemical progression free survival. Actas Urol Esp. 2008;32:792-8.
11. Khan MA, Partin AW. Management of patients with an increasing prostate specific antigen after radical prostatectomy. Curr Urol Rep. 2004;5:179.
12. Zudaire Bergera JJ, Martín-Marquina Aspiunza A, Sánchez Zalabardo D, Arocena García-Tapia J, Sanz Pérez G, Díez Caballero F, et al. Radical prostatectomy in clinically localized prostatic adenocarcinoma. Factors influencing biochemical progression free survival. Actas Urol Esp. 1999;23:333-41.
13. Egawa S, Suyama K, Arai Y, Matsumoto K, Tsukayama C, Kuwao S, et al. A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men. Jpn J Clin Oncol. 2001;31:74-81. (Pubitemid 32293968)
14. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen M-H, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168-72. (Pubitemid 29022390)
15. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74. (Pubitemid 28445094)
16. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-71. (Pubitemid 28259189)
17. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4. (Pubitemid 23175983)
18. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 1997;277:1445-51. (Pubitemid 27208886)
19. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti Jr JC, Leidich R, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology. 1995;46:205-12.
20. Gil Martínez P, Gil Sanz MJ, Allepuz Losa C, Borque Fernando A, Valdivia Navarro P, Rioja Sanz LA. Stage pT3 prostatic cancer after radical prostatectomy. Results in progression and survival. Actas Urol Esp. 2000;24:400-5.
21. Zudaire Bergera JJ, Martín-Marquina Aspiunza A, Sánchez Zalabardo D, Arocena García-Tapia J, Sanz Pérez G, Diez Caballero F, et al. Radical prostatectomy in clinically localized prostatic adenocarcinoma. Study of patients with positive margins and their impact on survival free from biochemical progression. Actas Urol Esp. 1999;23:835-42.
22. Zudaire Bergera JJ, López Ferrándiz J, Sánchez Zalabardo D, Arocena García-Tapia J, Sanz Pérez G, Díez Caballero F, et al. Radical prostatectomy in stage pT3C stage prostatic adenocarcinoma. Actas Urol Esp. 2000;24:468-74.
23. Lowe BA, Liebermann SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adyuvant therapy. J Urol. 1997;158:1452-6. (Pubitemid 27391217)
24. Paulson DF. Impact for radical prostatectomy in the management of clinically localized disease. J Urol. 1994;152: 1826-30. (Pubitemid 24322639)
25. Stein JB, De Kernion, Dorey F. Prostate specific antigen related to clinical status 1 to 14 years after radical prostatectomy. J Urol. 1991;67:626-31.
26. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, et al. Ki67 labeling indexin core needle biopsies independently predicts tumor-specific survival in prostate cancer. Human Pathol. 1998;29:949-54. (Pubitemid 28422042)
27. Bokemeyer C, Kuccyk MA, Hartmann JT, Serth J, Bathke W, Graubner M, et al. Overexpression of p53 oncoprotein predicts local recurrence and long-term survival following radical prostatectomy. Proc Ann Meet Am Soc Clin Oncol. 1997; 16:A1122.
28. Zudaire Bergera JJ, Sánchez Zalabardo D, Arocena García-Tapia J, Sanz Pérez G, Diez Caballero F, López Ferrandis J, et al. P53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival. Actas Urol Esp. 2000;24:307-13.
29. Partin AW, Piantadosi S, Marshall FF. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45: 831.
30. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Falnders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic ulrologic research endeavor database. J Urol. 2001;166: 1322-7. (Pubitemid 32862166)
31. Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC, McLeod DG, Srivastava S, et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer. 1997;79:952.
32. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001;57: 1033-7. (Pubitemid 32455561)
33. Porter CP, O'Donnell C, Crawford ED, Gamito EJ, Errejon A, Genega E, et al. Artificial neural network model to predict biochemical failure following radical prostatectomy. Mol Urol. 2001;5:159.